Pressure Ulcer Clinical Trial
— SKINCAREOfficial title:
Enhancing SKIN Health and Safety in Aged CARE: An Exploratory Cluster Randomized Pragmatic Trial in Aged Nursing Home Residents (SKINCARE)
Verified date | August 2021 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Aged long-term care receivers are affected by various adverse skin conditions like pressure ulcers, incontinence-associated dermatitis, dryness, intertrigo and many more. Prevention of these skin problems and the provision of general hygiene and skin care activities are key areas of nursing practice. Numerous condition specific guidelines are available and are implemented separately. The more guidelines exist, the more difficult it is for nurses to implement them all. On the other hand, there is a huge overlap in terms of aetiology, pathogenesis and prevention of aforementioned skin conditions. The overall aim of this trial is to test the feasibility and to estimate possible effects of a comprehensive skin care package targeting main nursing relevant skin problems at the same time. Therefore a study will be performed in nursing homes of the state of Berlin comparing the skin care package to standard care. Residents' safety and subjective wellbeing will increase combined with improvements in professional competence of nurses. An advisory board consisting of international experts agreed already to supervise the trial.
Status | Completed |
Enrollment | 405 |
Est. completion date | June 4, 2021 |
Est. primary completion date | June 4, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion/ Exclusion Criteria for Residents: Inclusion Criteria: - Living in the nursing home, - 65+ years, - 'Care degree 2' or higher according to SGB XI (Sozialgesetzbuch (Codebook of Social Law)), - Written informed consent (by legal representative if required) Exclusion Criteria: - Residents at end of life, - Any dermatological condition or skin affection requiring dermatological treatment, - Known allergies to any product ingredients Inclusion/ Exclusion Criteria for Nursing Homes: Inclusion Criteria: - Nursing home in the federal state of Berlin with at least n = 70 or more residents. - Expression of a clear commitment to implement the skin care algorithm if assigned to the intervention group, - Valid pressure ulcer prevention standard/algorithm is in place, - Written commitment to adherence to the trial procedures regardless of the outcome of randomisation. Exclusion criteria: - Nursing homes with less than n = 70 residents in the federal state of Berlin. Exclusion Criteria: - Nursing homes with less than n = 70 residents in the federal state of Berlin |
Country | Name | City | State |
---|---|---|---|
Germany | Charité - Universitätsmedizin Berlin | Berlin | |
Germany | Charité-Universitätsmedizin Berlin | Berlin |
Lead Sponsor | Collaborator |
---|---|
PD Dr. Jan Kottner |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Pressure Ulcers (PU) Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) | Proportions of newly developed PUs per person and per skin area to calculate the cumulative incidence | Week 12 +/- 1 | |
Primary | Incidence of Pressure Ulcers (PU) Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) | Proportions of newly developed PUs per person and per skin area to calculate the cumulative incidence | Week 24 +/- 1 | |
Primary | Location of Pressure Ulcers (PU) Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) | Classification according to NPUAP (National Pressure Ulcer Advisory Panel)/EPUAP (European Pressure Ulcer Advisory Panel) 2014 | Week 12 +/- 1 | |
Primary | Location of Pressure Ulcers (PU) Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) | Classification according to NPUAP (National Pressure Ulcer Advisory Panel)/EPUAP (European Pressure Ulcer Advisory Panel) 2014 | Week 24 +/- 1 | |
Primary | Incidence of Incontinence-associated Dermatitis (IAD) | Proportions of newly developed IAD per person and per skin area to calculate the cumulative incidence. The classification of IAD will be according to GLOBIAD (Ghent Global IAD Categorisation tool) and distinction between intact and eroded skin according to Proceedings of the Global IAD Expert Panel. | Week 12 +/- 1 | |
Primary | Incidence of Incontinence-associated Dermatitis (IAD) | Proportions of newly developed IAD per person and per skin area to calculate the cumulative incidence. The classification of IAD will be according to GLOBIAD (Ghent Global IAD Categorisation tool) and distinction between intact and eroded skin according to Proceedings of the Global IAD Expert Panel. | Week 24 +/- 1 | |
Primary | Incidence of Intertrigo | Proportions of newly developed intertrigo per person and skin area to calculate the cumulative incidence. Medical diagnoses according to ICD (international classification of diseases) 11. | Week 12 ± 1 | |
Primary | Incidence of Intertrigo | Proportions of newly developed intertrigo per person and skin area to calculate the cumulative incidence. Medical diagnoses according to ICD (international code of diseases) 11. | Week 24 ± 1 | |
Primary | Incidence of Skin Tears (ST) | Proportions of newly developed STs per person and skin area to calculate the cumulative incidence. Classification according to ISTAP (International Skin Tear Advisory Panel). | Week 12 ± 1 | |
Primary | Incidence of Skin Tears (ST) | Proportions of newly developed STs per person and skin area to calculate the cumulative incidence. Classification according to ISTAP (International Skin Tear Advisory Panel). | Week 24 ± 1 | |
Secondary | Overall Dry Skin Score (ODS) on face, trunk, arms, hands, feet, legs | Change in Overall Dry Skin score. ODS is a clinical assessment of the presence and severity of skin dryness using a five-point scale. A score of '0' indicates no skin dryness, whereas a score of '4' indicates advanced skin roughness, large scales, inflammation and cracks. | Week 0, Week 12 ± 1, Week 24 ± 1 | |
Secondary | Stratum Corneum Hydration (SCH) measurements on right lower leg lateral, right midvolar forearm | Change in Stratum Corneum Hydration. SCH was measured using the Corneometer CM 825 (Courage + Khazaka, Cologne, Germany). This measurement is based on the differences of the dielectric constant of water and other substances. With this device, only the moisture content in the stratum corneum is measured. The arbitrary units (a.u.) range from 0 to 120 where as higher readings indicate higher stratum corneum hydration.
Means of triplicate measurements per skin area in arbitrary units at right lower leg lateral, right midvolar forearm If measurements are not possible at right leg/arm (e.g. due to amputation) they will be conducted at contralateral skin areas |
Week 0, Week 12 ± 1, Week 24 ± 1 | |
Secondary | Transepidermal Water Loss (TEWL) on right lower leg lateral, right midvolar forearm | Change in Transepidermal water loss. TEWL was measured with the Tewameter TM 300 (Courage + Khazaka, Cologne, Germany). The probe captures the constant permeation of water through the stratum corneum in gram per hour per m2. The measuring probe contains a pair of sensors that are located in different distances to the skin surface to determine temperature and relative humidity above the skin surface. The humidity gradient between both sensors is used for calculating the transepidermal water loss. Higher values indicate a higher transepidermal water loss.
Means of duplicate measurements per skin area in g/m2/h at right lower leg lateral, right midvolar forearm If measurements are not possible at right leg/arm (e.g. due to amputation) they will be conducted at contralateral skin areas |
Week 0, Week 12 ± 1, Week 24 ± 1 | |
Secondary | Skin Surface pH on right lower leg lateral, right midvolar forearm | Change in Skin surface pH. Skin surface pH was measured with the Skin-pH-Meter PH 905 (Courage + Khazaka, Cologne, Germany), a planar glass electrode. The pH is a measure of acidity and alkalinity of a solution and it indicates the concentration of the hydrogen ions in an aqueous solution. Reference values of human skin have been reported to range from 4 to 6.
Means of duplicate measurements per skin area at right lower leg lateral, right midvolar forearm If measurements are not possible at right leg/arm (e.g. due to amputation) they will be conducted at contralateral skin areas |
Week 0, Week 12 ± 1, Week 24 ± 1 | |
Secondary | Skin surface temperature [°C] on right lower leg lateral, right midvolar forearm | Skin surface temperature was measured with the Skin-Thermometer ST 500 (Courage+Khazaka electronic GmbH).
Means of duplicate measurements per skin area in °C at right lower leg lateral, right midvolar forearm If measurements are not possible at right leg/arm (e.g. due to amputation) they will be conducted at contralateral skin areas |
Week 0, Week 12 ± 1, Week 24 ± 1 | |
Secondary | Quality of Life (QoL) (residents without cognitive impairment): WHO-Five Well-being Index (WHO = World Health Organization) | Self-completion of the WHO-Five Well-being Index by residents without cognitive impairment. The German version of the WHO-Five Well-being Index questionnaire published by the World Health Organization in 1998 will be used. Scores range from '5' (all the time) to '0' (never) for in total five items.The sum scores range from 0, indicating the lowest well-being, to 25, indicating the highest well-being. A cut-off score of < 13 is recommended. Means will be calculated.
? Means |
Week 0, Week 24 ± 1 | |
Secondary | Quality of Life (QoL) (cognitively impaired residents): QUALIDEM 18-Item Assessment (QUALIDEM = No original term, measurement instrument for proxy rating of quality of life in people with dementia) | The QUALIDEM assessment is a dementia-specific quality of life (QoL) instrument carried out by the nursing staff that allows a proxy-based QoL rating in all stages of dementia.The German version of the QUALIDEM version 2.0 published in 2015 will be used.Residents with a very severe dementia will answer the 18-item Instrument.To assess whether the resident is affected by mild to severe dementia or very severe dementia the global deterioration scale (GDS) will be used (see Outcome 22). | Week 0, Week 24 ± 1 | |
Secondary | Quality of Life (QoL) (cognitively impaired residents): QUALIDEM 37-Item Assessment | The QUALIDEM assessment is a dementia-specific quality of life (QoL) instrument carried out by the nursing staff that allows a proxy-based QoL rating in all stages of dementia.The German version of the QUALIDEM version 2.0 published in 2015 will be used.In case the resident is affected by a mild to severe dementia the 37-item assessment will be used.To assess whether the resident is affected by mild to severe dementia or very severe dementia the global deterioration scale (GDS) will be used (see Outcome 22). | Week 0, Week 24 ± 1 | |
Secondary | Itch Assessment | Self-completion of the 5-D itch scale by residents without cognitive impairment (according to GDS score of 1)
The score of the 5-D Itch scale ranges from '5' (no pruritus) to '25' (most severe pruritus) and contains five items measuring pruritus over the past two weeks. Means |
Week 0, Week 12 ± 1, Week 24 ± 1 | |
Secondary | Pain Assessment (residents without cognitive impairment): numeric rating scale | ? Self-completion of a numeric rating scale (NRS with total scores from 0: minimum pain to 10: maximum pain) to measure pain by residents without cognitive impairment. Means of the total score will be calculated. | Week 0, Week 12 ± 1, Week 24 ± 1 | |
Secondary | Pain Assessment (cognitively impaired residents): Verbal rating scale | ? Verbal rating scale (proxy rated) to measure pain in cognitively impaired residents (VRS with total scores from 0: minimum pain to 10: maximum pain). Means of the total score will be calculated. | Week 0, Week 12 ± 1, Week 24 ± 1 | |
Secondary | Assesment of dementia: Global Deterioration scale. | To assess whether the resident is affected by mild to severe dementia or very severe dementia the global deterioration scale (GDS) will be used. GDS scores from 2 to 6 indicate a mild to severe dementia and the 37-item assessment of the QUALIDEM tool will be used (see Outcome 18). A GDS score of 7 indicates very severe dementia and the 18-item QUALIDEM tool will be used (see Outcome 17). | Week 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03351049 -
An RCT on Support Surfaces for Pressure Ulcer Prevention
|
N/A | |
Completed |
NCT05112068 -
Comparative Assessment of Effectiveness and Safety of Methods for Skin and Hair Care in Severe Intensive Care Unit Patients
|
||
Completed |
NCT05575869 -
Evaluation of the Impact of the PRONEtect Education Hub vs. Classic Lecture, on the Competencies of Nursing Students
|
N/A | |
Completed |
NCT03220451 -
Use of Adhesive Elastic Taping for the Therapy of Medium/Severe Pressure Ulcers in Spinal Cord Injured Patients
|
N/A | |
Terminated |
NCT05234632 -
Study to Evaluate the PICO 14 Negative Pressure Wound Therapy System in the Management of Acute and Chronic Wounds
|
N/A | |
Completed |
NCT04540822 -
Peripheral Catheter Pressure Ulcer Prevention in Pediatry : Use of Compresses Versus Standard Care
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT02092870 -
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
|
Phase 2 | |
Completed |
NCT01438541 -
A Multi-centre Evaluation of the Performance of Window Dressings on Subjects With High Risk Pressure Ulceration
|
Phase 4 | |
Completed |
NCT00365430 -
SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes
|
N/A | |
Completed |
NCT04251897 -
Novel Support Surface to Alleviate Pressure Ulcer
|
N/A | |
Completed |
NCT03391310 -
Use of Honey for Pressure Ulcers in Critically Ill Children
|
N/A | |
Recruiting |
NCT04559165 -
Efficacy and Safety of Sericin and Chitosan Cream for Preventing and Limiting the Progressive of Pressure Sore
|
N/A | |
Completed |
NCT05646121 -
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
|
||
Not yet recruiting |
NCT06421454 -
Clinical Trial for the Evaluation of Melatonin in the Treatment of Pressure Ulcers
|
N/A | |
Terminated |
NCT05547191 -
Evaluate Efficacy and Safety of ChloraSolv When Treating Pressure Ulcers in Need of Debridement
|
N/A | |
Completed |
NCT05458050 -
An Investigation to Identify Subjects Admitted to Hospital With an Increased Risk of Developing Pressure Ulcers
|
N/A | |
Active, not recruiting |
NCT03048357 -
Effectiveness of Freedom Bed Compared to Manual Turning in Prevention of Pressure Injuries in Persons With Limited Mobility Due to Traumatic Brain Injury and/or Spinal Cord Injury.
|
N/A | |
Completed |
NCT06025370 -
Pressures During Prone Positions in Healthy Volunteers
|
N/A | |
Recruiting |
NCT05033470 -
A Multicentre Prospective Study Evaluating an Off-loading Mattress Overlay System in Healing of Stage 3 Pressure Ulcers
|
N/A |